Cellect Biotechnology EBIT

Cellect Biotechnology (APOP) currently reports a EBIT of $3.9M as of March 2026. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Cellect Biotechnology's EBIT history and peer comparisons.

Cellect Biotechnology's EBIT of $3.9M is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Cellect Biotechnology reported $3.9M in EBIT as of March 2026. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $3.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Cellect Biotechnology, and consider following APOP for alerts when major investors trade the stock.

Cellect Biotechnology is classified in the Healthcare sector. On EBIT, it currently shows $3.9M versus a sector average near $110B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing APOP with unrelated industries.